Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Janku

Showing results (11-20 of 277) with videos related to

Pageof 28
Sort By:
Pharmacology & Therapeutics|December 17, 2013
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathwayJiri Polivka, Filip Janku
Biomarkers in Medicine|July 16, 2015
Cell-free DNA as a novel marker in cancer therapyShumei Kato, Filip Janku
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2012
Ridaforolimus in advanced sarcomas: a leap forward or missed opportunity?Ignacio Garrido-Laguna, Filip Janku
Cancer Treatment Reviews|April 15, 2015
Targeted therapies for advanced Ewing sarcoma family of tumorsYunyun Jiang, Joseph Ludwig, Filip Janku
Lung Cancer (Amsterdam, Netherlands)|June 12, 2002
Highlights from the 7th central European lung cancer conferencePetr Zatloukal, Lubos Petruzelka, Filip Janku
Irish Journal of Medical Science|September 30, 2010
Unusual presentation of gastrointestinal stromal tumor with early cerebral involvementFilip Janku, David Kidney, John Coyne
Oncotargets and Therapy|November 4, 2014
Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectivesManojkumar Bupathi, Ahmed Kaseb, Filip Janku
Expert Review of Molecular Diagnostics|November 13, 2015
Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?Jiri Polivka, Martin Pesta, Filip Janku
Molecular Cancer Therapeutics|May 27, 2010
Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra)Hazem El-Osta, Filip Janku, Razelle Kurzrock
Cancers|July 24, 2021
Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and ScreeningJacob J Adashek, Filip Janku, Razelle Kurzrock
Pageof 28

Showing results (11-20 of 277) with videos related to

Sort By:
Pageof 28
Pharmacology & Therapeutics|December 17, 2013
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathwayJiri Polivka, Filip Janku
Biomarkers in Medicine|July 16, 2015
Cell-free DNA as a novel marker in cancer therapyShumei Kato, Filip Janku
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2012
Ridaforolimus in advanced sarcomas: a leap forward or missed opportunity?Ignacio Garrido-Laguna, Filip Janku
Cancer Treatment Reviews|April 15, 2015
Targeted therapies for advanced Ewing sarcoma family of tumorsYunyun Jiang, Joseph Ludwig, Filip Janku
Lung Cancer (Amsterdam, Netherlands)|June 12, 2002
Highlights from the 7th central European lung cancer conferencePetr Zatloukal, Lubos Petruzelka, Filip Janku
Irish Journal of Medical Science|September 30, 2010
Unusual presentation of gastrointestinal stromal tumor with early cerebral involvementFilip Janku, David Kidney, John Coyne
Oncotargets and Therapy|November 4, 2014
Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectivesManojkumar Bupathi, Ahmed Kaseb, Filip Janku
Expert Review of Molecular Diagnostics|November 13, 2015
Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?Jiri Polivka, Martin Pesta, Filip Janku
Molecular Cancer Therapeutics|May 27, 2010
Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra)Hazem El-Osta, Filip Janku, Razelle Kurzrock
Cancers|July 24, 2021
Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and ScreeningJacob J Adashek, Filip Janku, Razelle Kurzrock
Pageof 28